Provided by Tiger Trade Technology Pte. Ltd.

MannKind

5.46
-0.4500-7.61%
Post-market: 5.460.00000.00%16:10 EST
Volume:4.49M
Turnover:25.32M
Market Cap:1.68B
PE:55.78
High:5.95
Open:5.88
Low:5.46
Close:5.91
52wk High:6.51
52wk Low:3.38
Shares:307.07M
Float Shares:300.98M
Volume Ratio:0.87
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0979
EPS(LYR):0.1005
ROE:32.74%
ROA:9.95%
PB:-37.63
PE(LYR):54.31

Loading ...

MannKind Targets Newly Diagnosed Youth With Afrezza: What Investors Should Watch

TIPRANKS
·
Jan 17

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Dow Jones
·
Jan 13

How 2026 FDA Decisions on Afrezza and FUROSCIX At MannKind (MNKD) Have Changed Its Investment Story

Simply Wall St.
·
Jan 10

Stuart A. Tross, Chief People & Workplace Officer, Reports Disposal of MannKind Corporation Common Shares

Reuters
·
Jan 10

Assessing MannKind (MNKD) Valuation As Regulatory Catalysts And Pipeline Updates Draw Investor Attention

Simply Wall St.
·
Jan 09

Multiple 2026 Regulatory, Pipeline, and Partnership Catalysts Underscore MannKind’s Underappreciated Growth Potential and Support Reiterated Buy Rating

TIPRANKS
·
Jan 09

MannKind shares not pricing in ‘multiple tailwinds,’ says H.C. Wainwright

TIPRANKS
·
Jan 09

BRIEF-Mannkind Provides Business Updates And 2026 Growth Drivers

Reuters
·
Jan 08

MannKind Reports Record Q4 Revenue and Highlights 2026 Growth Drivers

Reuters
·
Jan 08

Press Release: MannKind Provides Business Updates and 2026 Growth Drivers

Dow Jones
·
Jan 08

MannKind Corporation Secures Five New U.S. Patents for FUROSCIX ReadyFlow Autoinjector

Reuters
·
Dec 23, 2025

MannKind Shares FUROSCIX® Business Updates

GlobeNewswire
·
Dec 23, 2025

MannKind CEO Michael Castagna Reports Disposal of Common Shares

Reuters
·
Dec 17, 2025

MannKind Corporation Issues Amendment on scPharmaceuticals Acquisition Filing

Reuters
·
Dec 16, 2025

MannKind (MNKD): Evaluating Valuation After FDA Acceptance of the FUROSCIX ReadyFlow Autoinjector sNDA

Simply Wall St.
·
Dec 15, 2025

MannKind Corp : Leerink Partners Raises Target Price to $9 From $7

THOMSON REUTERS
·
Dec 09, 2025

MannKind CEO Michael Castagna Reports Disposal of Common Shares

Reuters
·
Dec 05, 2025

BRIEF-Mannkind Announces U.S. FDA Accepts For Review Its Supplemental New Drug Application (SNDA) Of Furoscix Readyflow™ Autoinjector

Reuters
·
Dec 01, 2025

MannKind Corp - Pdufa Target Action Date Set for July 26, 2026

THOMSON REUTERS
·
Dec 01, 2025

MannKind Announces U.S. FDA Accepts for Review Its Supplemental New Drug Application (Snda) of Furoscix Readyflow™ Autoinjector for the Treatment of Edema in Adults With Chronic Heart Failure or Chronic Kidney Disease

THOMSON REUTERS
·
Dec 01, 2025